Background: Mixed evidence suggests that second-generation antidepressants may increase the risk of cardiovascular and cerebrovascular events. Objective: To assess whether antidepressant use is associated with acute coronary heart disease (CHD), stroke, cardiovascular disease (CVD) death, and all-cause mortality. Methods: Secondary analyses of the Reasons for Geographic and Racial Differences in Stroke (REGARDS) longitudinal cohort study were conducted. Use of selective serotonin reuptake inhibitors, serotonin and norepinephrine reuptake inhibitors, bupropion, nefazodone, and trazodone was measured during the baseline (2003)(2004)(2005)(2006)(2007) in-home visit. Outcomes of CHD, stroke, CVD death, and all-cause mortality were assessed every 6 months and adjudicated by medical record review. Cox proportional hazards time-to-event analysis followed patients until their first event on or before December 31, 2011, iteratively adjusting for covariates. Results: Among 29 616 participants, 3458 (11.7%) used an antidepressant of interest. Intermediate models adjusting for everything but physical and mental health found an increased risk of acute CHD (hazard ratio [HR] = 1.21; 95% CI = 1.04-1.41), stroke (HR = 1.28; 95% CI = 1.02-1.60), CVD death (HR = 1.29; 95% CI = 1.09-1.53), and allcause mortality (HR = 1.27; 95% CI = 1.15-1.41) for antidepressant users. Risk estimates trended in this direction for all outcomes in the fully adjusted model but only remained statistically associated with increased risk of all-cause mortality (HR = 1.12; 95% CI = 1.01-1.24). This risk was attenuated in sensitivity analyses censoring follow-up time at 2 years (HR = 1.37; 95% CI = 1.11-1.68). Conclusions: In fully adjusted models, antidepressant use was associated with a small increase in all-cause mortality.
Introduction
The association between antidepressant use and risk of cardiovascular and cerebrovascular disease remains controversial. Antidepressant use has been linked to thicker arteries, which could contribute to the risk of heart disease and stroke. 1 One study reported that the carotid intima-media thickness was 5% greater for twins taking versus not taking antidepressants. 1 This was true both for selective serotonin reuptake inhibitors (SSRIs) and other antidepressants (which included serotonin and norepinephrine reuptake inhibitors [SNRIs], tricyclic antidepressants [TCAs], monoamine oxidase inhibitors, and other miscellaneous antidepressants). For cerebrovascular disease, 1 prior study found that patients with major depression taking SSRIs as monotherapy over a 19-year period had a higher risk of stroke (adjusted risk ratio = 1.18) if they had taken a drug with high as opposed to low affinity for the serotonin transporter. 2 Another large study of postmenopausal women found that those taking TCAs and SSRIs were 45% more likely to suffer a fatal stroke, 3 and the overall death rate was 32% higher for those on the drugs. Despite these studies, the risk of cardiovascular and cerebrovascular events with antidepressant use is not a large consideration in clinical practice. 4 Data from the Reasons for Geographic and Racial Differences in Stroke (REGARDS) study provide a unique resource for evaluating cardiovascular and cerebrovascular risk with antidepressants. REGARDS is a longitudinal cohort study of 30 239 whites and African Americans, designed to examine factors associated with excess strokerelated mortality in the Southeastern United States and among African Americans. The REGARDS-Myocardial Infarction (MI) ancillary study provides data on additional coronary heart disease (CHD) outcomes. The goals of our analyses were to review baseline antidepressant use among REGARDS participants and to assess associations between antidepressant use and CHD, stroke, cardiovascular disease (CVD) death, and all-cause mortality.
Methods

Study Participants
The REGARDS study is a national, population-based, biracial, longitudinal cohort study designed to examine underlying causes for racial and regional differences in stroke and CHD. 5 Between January 2003 and October 2007, 30 239 individuals were enrolled, including 42% African Americans, 58% whites, 45% men, and 55% women. The sample includes 21% of participants from the Stroke Buckle (coastal plain region of North Carolina, South Carolina, and Georgia), 35% from the remaining areas of the Stroke Belt states (remainder of North Carolina, South Carolina, and Georgia, plus Alabama, Mississippi, Tennessee, Arkansas, and Louisiana), and 44% from the other 40 contiguous states (referred to as non-Belt). The study protocol was reviewed and approved by the institutional review boards at the participating institutions, and all participants provided informed consent.
Data Collection
Baseline data were collected through a telephone interview, self-administered questionnaires, and an in-home examination. Telephone interviews collected data on sociodemographics, health behaviors, health status, and self-report of prior diagnoses of comorbid conditions. Following the telephone interview, trained technicians conducted an in-home visit that included review of medication bottles, 2 blood pressure measurements, the collection of blood and urine samples, and an electrocardiogram (ECG). 5 Participants or their proxies were contacted by telephone every 6 months following baseline to assess for stroke, CHD, and all-cause mortality. Medical records were retrieved and expert adjudicated for suspected stroke and CHD-related hospitalizations and deaths.
Antidepressant Exposure
Medication use was determined by the in-home medication bottle review. We included only the newer, most commonly used second-generation antidepressants, classified as SSRIs (citalopram, escitalopram, fluoxetine, fluvoxamine, paroxetine, and sertraline), SNRIs (venlafaxine and duloxetine), and miscellaneous agents (bupropion, nefazodone, and trazodone).
Study Outcomes
Death certificates, medical records, and autopsy reports were obtained to adjudicate cause of death, and cardiovascular outcomes were adjudicated using methods previously described. 6 Prospectively assessed outcomes included CHD, stroke, CVD death, and all-cause mortality.
Coronary Heart Disease. The occurrence of CHD events was defined as nonfatal MI or acute CHD death. Medical records were reviewed by trained clinician adjudicators to determine the study end points, following published guidelines. 7, 8 Specifically, medical records were examined for the following: presence of signs or symptoms suggestive of ischemia; a rising and/or falling pattern in cardiac troponin or creatine kinase-MB over 6 or more hours, with a peak value greater than or equal to twice the upper limit of normal (diagnostic cardiac enzymes); and ECG changes consistent with ischemia or MI, guided by the Minnesota Code and classified as evolving diagnostic, positive, nonspecific, or not consistent with ischemia. 9,10 Additionally, following published guidelines, interviews with family members who were present around the time of death, baseline history, medical records in the last year of life, death certificates, the National Death Index, and autopsy reports were collected and reviewed to determine if the death was a CHD death. 7, 8 Stroke. Medical records, neuroimaging, and other diagnostic reports were obtained when participants self-reported a possible stroke or stroke symptoms or when a participant died with a potential cause of stroke. Final adjudication was based on the World Health Organization's definition of stroke and/or imaging results consistent with a stroke. 11, 12 care, which was measured by participant self-report of a usual source of care. Measures of health behaviors included cigarette smoking status (never, past, or current), alcohol use (defined as heavy: ≥7 drinks/wk for women, ≥14 drinks/wk for men; moderate: 1-7 for women, 1-14 for men; and none), report of engaging in no physical activity in the past week that worked up a sweat, and adherence to medications (with good adherence defined as a "no" response to all 4 questions of the Morisky scale). 13 Medical conditions included hypertension (defined as systolic blood pressure ≥140 mm Hg or diastolic blood pressure ≥90 mm Hg as assessed by the average of 2 measurements taken by a trained technician using a standard protocol and regularly tested aneroid sphygmomanometer, measured in the fasting state after the participant was seated for 5 minutes with both feet on the floor), diabetes (defined as taking insulin or oral hypoglycemic agents, or based on the baseline blood collection, a fasting blood glucose ≥126 mg/dL, or a nonfasting blood glucose ≥200 mg/ dL), and atrial fibrillation (defined as self-reported history or evidence on an ECG performed during the in-home assessment). Preventive medication use included self-reported use of antihypertensive medications, statins, or aspirin. Physiological risk factors were captured by measures of total cholesterol, high-density lipoprotein cholesterol, systolic blood pressure, body mass index, high-sensitivity C-reactive protein, urinary albumin to creatinine ratio, and QT interval corrected for heart rate. Finally, markers of physical and mental health were measured by the physical and mental component scores of the Short Form-12 (SF-12) functional status scale, presence of depressive symptoms (defined as a score ≥4 on the 4-item version of the Centers for Epidemiologic Study Depressive Scale [CES-D]), and moderate to high stress (defined as a score of 3 or higher on Cohen's Perceived Stress Scale [PSS]). 14 The use of benzodiazepines was controlled for because these drugs could be markers of mental health. Use of TCAs, which have previously been shown to be associated with the outcomes of interest, 15 were considered only in sensitivity analyses that excluded participants on these drugs.
Participants with a history of CHD, stroke, abdominal aortic aneurysm, or peripheral arterial disease were considered to have a history of CVD. History of CHD at baseline was defined by a self-reported history or ECG evidence of MI or a self-reported history of a coronary revascularization procedure. History of stroke was defined on the basis of participant self-report.
Statistical Analysis
Descriptive statistics for the antidepressant use categories were obtained by using unadjusted χ 2 tests for the categorical characteristics and the Student t test for continuous characteristics. For each outcome, time-to-event analysis was performed; participants were followed until their first event.
Incident events through December 31, 2011, were used for this analysis.
Sequentially adjusted Cox proportional hazards models were fit to examine hazard ratios (HRs) for antidepressant users compared with nonusers for the 4 end points of CHD, stroke, CVD death, and all-cause mortality. Proportionality assumptions were tested via the interaction of antidepressant use with the natural log of follow-up time. Initial unadjusted Cox proportional hazards models included only the antidepressant exposure. Model 1 adjusted for demographic and socioeconomic characteristics. Model 2 adjusted for model 1 covariates plus health behaviors, medical conditions (except hypertension), preventive medication use, and physiological risk factors. Baseline atrial fibrillation was adjusted for with all outcome measures except for CHD. Model 3 adjusted for all the model 2 covariates plus markers of physical and mental health. The SF-12 mental health component score was not included in this model because of collinearity with the CES-D. Benzodiazepine use was included in model 3, and sensitivity analyses considered each model after excluding baseline TCA users. Multivariable multiple imputation by chained equations was used to replace missing data in covariates in 10 data sets with the sample bootstrapping. 16 We conducted several stratified analyses. First, we stratified analyses by history of baseline CVD. Next, because of the cross-sectional antidepressant measurement, we explored the impact of censoring follow-up intervals at 0 to 2 years, 0 to 4 years, and 0 years to end of follow-up. Finally, Kaplan-Meier survival curves and log-rank tests explored the association of different medication classes with the study end points. Antidepressant classes were defined as SSRIs, SNRIs, miscellaneous antidepressants, and multiple drug use (eg, SSRI + SNRI, SSRI + miscellaneous antidepressant).
Results
Of the 30 239 REGARDS participants enrolled between January 2003 and October 2007, 545 were missing followup and excluded from the initial cohort (n = 29 694). An additional 70 participants were missing an in-home medication review, and 8 participants had a documented stroke after their interview and prior to the in-home visit, leaving an analysis cohort of 29 616 participants. Of these participants, 3458 (11.7%) were using an eligible antidepressant at the time of the baseline visit. Characteristics of the antidepressant users and nonusers are shown in Table 1 . Of the antidepressant users, 2253 used SSRI monotherapy, 476 used SNRI monotherapy, 412 used one of the miscellaneous antidepressants, and 317 used multiple eligible drugs (eg, 58% of the 317 used an SSRI plus a miscellaneous drug).
Noteworthy differences were observed between antidepressant users and nonusers. For example, compared with nonusers, antidepressant users were younger (mean age = 62.6 vs 65.2 years), more likely female (47% vs 29%), more likely White (43% vs 24%), and more likely to have a regular source of care (83% vs 79%). We also observed differences across groups in blood pressure, antihypertensive medication and statin use, smoking and alcohol status, exercise, body mass index, and other physical and mental health indicators. The antidepressant use group tended to have higher perceived stress (67.5% vs 49.6% had PSS scores ≥3), more commonly used a benzodiazepine (17.1% vs 3.8%), and had lower medication adherence (63.6% vs 71.2%) than antidepressant nonusers. Among all participants, 759 stroke events, 1618 CHD events, 1373 CVD deaths, and 3883 deaths of any cause were observed. An increased risk of CHD among antidepressant users can be observed in the cumulative incidence plots in Figure 1 (panel A log-rank P = 0.01). For the other outcomes, an increased risk was not observed for antidepressant users in the unadjusted cumulative incidence plots (log-rank P > 0.05 for Figure 1 ; panels B-D). In the all-cause mortality analysis (Figure 1, panel D) , we noted an intersection of the cumulative incidence curves for those who had follow-up time greater than 7 years, and this was detected as a violation in proportionality assumption testing (P = 0.04 for the interaction of antidepressant use with the natural log of follow up time). Importantly, however, the intersection of the cumulative incidence curves occurs long after our cross-sectional antidepressant exposure measure, and should be interpreted cautiously.
Consistent with the cumulative incidence plots, the unadjusted HR (Table 2) suggested an increased risk of CHD for antidepressant users compared with nonusers. Stratified analysis indicated that this increase in risk was only significant among those who had baseline CVD. In our iterative model building, we observed interesting changes in the antidepressant HRs. For example, when we added demographic and socioeconomic factors to the model (Table 2 , model 1), the antidepressant HRs were significant for all of the outcomes. When we added health behaviors, medical conditions, preventive medication use, and physiological risk factors to the models (Table 2, model 2), the HRs remained statistically significant but decreased in relative magnitude. With the exception of the all-cause mortality model, stratified analyses suggested that antidepressant-associated increase in risk was magnified among those participants with baseline CVD. In the fully adjusted models, when markers of physical and mental health were added (Table 2, model 3), all HRs were still greater than 1.0, but antidepressant use only was statistically significantly associated with increased risk of allcause mortality (HR = 1.12; 95% CI = 1.01-1.24). Stratified analyses found an increased risk of stroke in antidepressant users who had baseline CVD (HR = 1.37; 95% CI = 1.00-1.88).
In sensitivity analyses, models including versus excluding TCA users were similar (data not shown). Additionally, with follow-up time censored at 2 years (Table 3) , we found an increased risk of all-cause mortality with antidepressants (HR = 1.37; 95% CI = 1.11-1.68). This increased risk was isolated to those who had baseline CVD (HR = 1.41; 95% CI = 1.08-1.83). When censoring follow-up time at 4 years, we did not observe any antidepressant-related increase in risk for cardiovascular outcomes.
Sample sizes in REGARDS were insufficient to adequately evaluate cardiovascular risk among individual antidepressant agents or drug groups with similar mechanisms, but we still explored patterns of cardiovascular outcomes among classes of agents. Visual inspection of these patterns suggests that participants taking multiple antidepressants or SSRIs may have a slightly higher rate of cardiovascular events (data not shown).
Discussion
The REGARDS study is a particularly valuable observational study because of its longitudinal follow-up, rigorous measurement of cardiovascular outcomes, and diverse participant population. 5 Our analyses assessed how baseline antidepressant exposure might be related to cardiovascular events. Fully adjusted models found a small but potentially meaningful increased risk of all-cause mortality for those taking antidepressants.
Through iterative model building, we also observed that potential antidepressant-related risk of cardiovascular and 44 (1.07-1.95)  1.43 (1.05-1.94)  1.37 (1.00-1.88 20 (1.04-1.39)  1.58 (1.34-1.81)  1.21 (1.04-1.41 22 (1.02-1.47)  1.38 (1.14-1.67 The reference group includes participants not taking antidepressants at baseline. Hazard ratios (HRs) are for antidepressant use. All outcomes were assessed on or before December 31, 2011, for antidepressant use overall and stratified by baseline history of cardiovascular events. Model 1 adjusts for demographic and socioeconomic characteristics: age sex, race, region, education, income, and having a usual source of care. Model 2 adjusts for model 1 covariates plus health behaviors of smoking, alcohol use, physical activity, and medication adherence; medical conditions of diabetes and baseline atrial fibrillation (for all end points but not coronary heart disease [CHD]); preventive medication use of statins, aspirin, and antihypertensive medication; and physiological risk factors of total cholesterol, high-density lipoprotein cholesterol, systolic blood pressure, body mass index, corrected QT, log of urinary albumin to creatinine ratio (ACR), log of C-reactive protein (CRP), and baseline cardiovascular disease (CVD), including history of CHD, stroke, aortic aneurysm or peripheral artery disease (baseline CVD only in overall models). Model 3 adjusts for model 2 covariates plus markers of physical and mental health, including the Short Form-12 physical health component, moderate to high stress (Perceived Stress Scale score ≥ 3), depressive symptoms (Centers for Epidemiologic Study Depressive Scale score ≥ 4), and benzodiazepine use. Missing data in covariates are imputed using chain equations in 10 data sets with the sample bootstrapping. Bold refers to P < 0.05. cerebrovascular events appears to be partially explained by other risk factors and almost completely explained when also considering markers of physical and mental health. This suggests that antidepressant use may, to some degree, be an indicator of other underlying physical or behavioral constructs that influence the risk of cardiovascular events rather than a direct cause. This is consistent with past research that suggests that depression itself is actually associated with increased cardiovascular events and death [17] [18] [19] and that careful management of depression can decrease mortality and improve cardiovascular outcomes. 20, 21 Over the past 15 years, the second-generation antidepressants considered in our analyses have been the most commonly used antidepressant agents. The US Food and Drug Administration labeling for most of these products includes at least some mention of the possibility for cardiovascular-related adverse events, such as QTc prolongation, sudden death, and MI. Our study provides additional evidence to support a marginally significant increase in risk of all-cause mortality with second-generation antidepressants. Additionally, although our fully adjusted models were not statistically significant for the outcomes of CHD, stroke, and acute CVD death, it should be noted that the HR point estimates for these models continued to remain elevated and were numerically greater than the point estimates for all-cause mortality. We believe that this is a function of the fact that there were fewer of these events compared to the all-cause mortality model, and therefore, the 95% confidence intervals were wider. The clinical interpretation of this finding is subject to further debate.
For our primary analysis we combined antidepressant users into one group and compared users with nonusers. However, prior research has suggested that all antidepressants may not have the same risk profile. For example, one study reported an adjusted risk ratio of 1.18 for strokes when comparing high-affinity SSRIs with low-affinity SSRIs. 2 We attempted to analyze specific drug types but found limited sample size, and these analyses also violated the proportionality assumption (data not shown). However, we observed some trends that might be indicative of differences across drugs, and this warrants further investigation, particularly for the SSRIs and multiple medication users. Our study also did not consider the possible role of drugdrug interactions, which could be a clinically meaningful consideration for some antidepressants. 22 The REGARDS study provides rich assessment of cardiovascular events and covariates, but our analyses may still be limited by unmeasured confounding. The most important limitation of our study is the cross-sectional baseline measure of antidepressant use. Although the REGARDS study methods used a rigorous assessment of pill bottles by trained personnel, 5 medication doses were not recorded, and postbaseline assessments of antidepressant use were not conducted. Without antidepressant doses, we could not consider whether a dose-response relationship exists. Because we did not have a longitudinal measure of antidepressant use, our exposure measurement is subject to misclassification bias, and this bias is likely to increase over time because antidepressants can be used episodically. For depression, for example, acute and continuation treatment may be less than 1 year in duration, as opposed to maintenance treatment, which is more consistent in treating a chronic illness.
In trying to evaluate the potential impact of this misclassification bias, we considered how long participants using an antidepressant at baseline might remain on that antidepressant. A Dutch study previously reported that almost 30% of antidepressant users took the drugs for more than 1 year. 23 A more recent US analysis found that, as of 2010, 66% of antidepressant users continued antidepressant use for more than 2 years. 24 Based on these estimates, we anticipate that at least half of REGARDS participants who used antidepressants at baseline might still be on the antidepressant after 2 years of follow-up.
Another exposure measurement consideration relates to whether antidepressant-related cardiovascular events might be expected early on in treatment or whether risk increases with longer duration of treatment. A British study suggests that risk of antidepressant-related all-cause mortality, MI, and stroke may be highest in the first 28 days of treatment, and risk appears to decline over time. 25 This argues that regardless of exposure misclassification, we likely could have observed relevant events early on during participant follow-up if the events were attributable to antidepressant use.
Our study adds to the existing literature and supports some degree of association between antidepressant use and mortality, even after considering depressive symptoms. [1] [2] [3] Clinicians and patients should be aware of a small but potentially clinically relevant increase in the risk of cardiovascular events and all-cause mortality.
